|
시장보고서
상품코드
2052568
알츠하이머병 치료제 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Alzheimers Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
알츠하이머병 치료제 시장은 2026년에 62억 4,000만 달러에 달하고, 2033년에 127억 2,000만 달러에 이를 전망입니다. 2026-2033년 CAGR은 10.7%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 62억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 10.70% | 시장 규모 예측(2033년) : | 127억 2,000만 달러 |
알츠하이머병은 기억력과 인지 기능을 서서히 손상시키는 진행성 신경퇴행성 질환입니다. 이는 고령자의 치매에서 가장 흔한 원인입니다. 전 세계 알츠하이머병 치료제 시장의 성장은 전 세계 알츠하이머병 유병률 증가에 힘입어 이루어지고 있습니다. 세계보건기구(WHO)에 따르면, 전 세계적으로 약 5,000만 명이 치매를 앓고 있으며, 매년 약 1,000만 명의 신규 환자가 발생하고 있습니다. 알츠하이머병의 근본적인 병태생리를 표적으로 하는 새로운 병태수식제의 승인 및 출시 증가가 예측 기간 동안 시장 성장을 견인할 가능성이 있습니다.
시장 역학
세계 알츠하이머병 치료제 시장의 성장은 고령 인구 증가, 알츠하이머병 유병률 상승, 새로운 질병 수정 치료제의 도입, 의료비 증가, 그리고 이 질환에 대한 인식 제고 등에 힘입어 견인되고 있습니다. 그러나 의약품 연구 개발에 따른 높은 비용이나 후기 임상시험의 실패가 시장 성장을 저해할 가능성이 있습니다. 고령 인구가 많은 개발도상국 지역은 큰 성장 기회를 제공합니다. 조기 진단 분야의 기술적 진보와 질병 병리에 대한 이해의 심화 또한 새로운 기회를 가져올 가능성이 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 세계 알츠하이머병 치료제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 전 세계 알츠하이머병 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계의 알츠하이머병 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있습니다.
목차
제1장 조사 목적 및 전제 조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 알츠하이머병 치료제 시장 : 약제 클래스별(2021-2033년)
제5장 세계의 알츠하이머병 치료제 시장 : 투여 경로별(2021-2033년)
제6장 세계의 알츠하이머병 치료제 시장 : 유통 채널별(2021-2033년)
제7장 세계의 알츠하이머병 치료제 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고 문헌 및 조사 방법
KTH 26.06.17Alzheimers Drugs Market is estimated to be valued at USD 6.24 Bn in 2026 and is expected to reach USD 12.72 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.24 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.70% | 2033 Value Projection: | USD 12.72 Bn |
Alzheimer's disease is a progressive neurodegenerative disease that slowly destroys memory and cognitive skills. It is the most common cause of dementia among older people. Global Alzheimer's drugs market growth is driven by rising prevalence of Alzheimer's disease worldwide. According to WHO, around 50 million people globally have dementia with nearly 10 million new cases every year. Rising approval and launch of novel disease modifying drugs that target the underlying pathophysiology of Alzheimer's can drive the market growth over the forecast period.
Market Dynamics
Global Alzheimer's drugs market growth is driven by rising geriatric population, increasing prevalence of Alzheimer's disease, introduction of novel disease modifying drugs, growing healthcare expenditure and rising awareness about the condition. However, high costs associated with drug R&D and failure of late stage clinical trials can hamper the market growth. Developing regions with large elderly populations an offer significant growth opportunities. Technological advancements in early diagnosis and advancements in understanding the disease pathology can also offer new opportunities.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Alzheimer's drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global Alzheimer's drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer's drugs market.
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Cholinesterase Inhibitors
- Donepezil
- Rivastigmine
- Galantamine
- NMDA Receptor Antagonist
- Memantine
- Combination Therapy
- Donepezil and Memantine
- Pipeline Drugs
- Aducanumab
- Lecanemab
- Donanemab
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie, Inc.
- Teva Pharmaceuticals Ltd.
- Eisai Co., Ltd.
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Novartis AG
- Zydus Lifesciences Ltd (CADILA)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Ltd.
- Amneal Pharmaceuticals Inc.
- Macleods Pharmaceuticals Ltd.
- Viatris Inc.
- Lupin Ltd.
- Cipla Ltd.
- Torrent Pharmaceuticals Ltd.
- Unichem laboratories ltd
- Lannett Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Alzheimer's Drugs Market, By Drug Class, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cholinesterase Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Donepezil
- Rivastigmine
- Galantamine
- NMDA Receptor Antagonist
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Memantine
- Combination Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Donepezil and Memantine
- Pipeline Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Aducanumab
- Lecanemab
- Donanemab
5. Global Alzheimer's Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Alzheimer's Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Alzheimer's Drugs Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zydus Lifesciences Ltd (CADILA)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dr. Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aurobindo Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Macleods Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Unichem laboratories ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lannett Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie, Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
